BRPI0507680A - partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas - Google Patents

partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas

Info

Publication number
BRPI0507680A
BRPI0507680A BRPI0507680-3A BRPI0507680A BRPI0507680A BR PI0507680 A BRPI0507680 A BR PI0507680A BR PI0507680 A BRPI0507680 A BR PI0507680A BR PI0507680 A BRPI0507680 A BR PI0507680A
Authority
BR
Brazil
Prior art keywords
calcium phosphate
methods
manufacture
phosphate particles
particles
Prior art date
Application number
BRPI0507680-3A
Other languages
English (en)
Inventor
William W Lee
Original Assignee
Nod Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nod Pharmaceuticals Inc filed Critical Nod Pharmaceuticals Inc
Publication of BRPI0507680A publication Critical patent/BRPI0507680A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PARTìCULAS DE FOSFATO DE CáLCIO TERAPêUTICAS E MéTODOS DE FABRICAçãO E USO DAS MESMAS. A presente invenção provê nanopartículas de fosfato de cálcio encapsuladas com macromoléculas biologicamente ativas. As partículas podem ser usadas como veículos de macromolécula biologicamente ativa para aplicação das macromoléculas. A invenção também provê métodos de fabricação e uso das partículas.
BRPI0507680-3A 2004-02-13 2005-02-11 partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas BRPI0507680A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54469304P 2004-02-13 2004-02-13
PCT/US2005/004247 WO2005084637A2 (en) 2004-02-13 2005-02-11 Particles comprising a core of calcium phosphate nanoparticles, a biomolecule and a bile acid, methods of manufacturing, therapeutic use thereof

Publications (1)

Publication Number Publication Date
BRPI0507680A true BRPI0507680A (pt) 2007-07-17

Family

ID=34919321

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507680-3A BRPI0507680A (pt) 2004-02-13 2005-02-11 partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas

Country Status (14)

Country Link
US (1) US7651694B2 (pt)
EP (1) EP1720520B1 (pt)
JP (1) JP5103022B2 (pt)
KR (1) KR20070002014A (pt)
CN (1) CN1993113B (pt)
AT (1) ATE470433T1 (pt)
AU (1) AU2005219372A1 (pt)
BR (1) BRPI0507680A (pt)
CA (1) CA2555921A1 (pt)
DE (1) DE602005021756D1 (pt)
ES (1) ES2344303T3 (pt)
MX (1) MXPA06009222A (pt)
RU (1) RU2006132735A (pt)
WO (1) WO2005084637A2 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007526322A (ja) * 2004-03-02 2007-09-13 マサチューセッツ インスティテュート オブ テクノロジー ナノセル薬物送達系
WO2007114881A1 (en) * 2006-01-24 2007-10-11 Nexbio, Inc. Technology for preparation of macromolecular microspheres
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
WO2009038591A1 (en) * 2007-09-17 2009-03-26 Yale University Bile salt colloids and methods of making and using thereof
US20100283570A1 (en) * 2007-11-14 2010-11-11 Lavoie Adrien R Nano-encapsulated magnetic particle composite layers for integrated silicon voltage regulators
US20120128767A1 (en) * 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
EP2480210A4 (en) 2008-09-23 2016-07-13 Lab Skin Care Inc ACTUATED UNIFORMS, RIGID, SPHERICAL NANOPOROUS CALCIUMOPHOSPHATE PARTICLES AND METHOD FOR THEIR USE AND MANUFACTURE
US9901551B2 (en) * 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
KR20180114970A (ko) * 2009-05-06 2018-10-19 라보라토리 스킨 케어, 인크. 활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
WO2013025951A1 (en) * 2011-08-16 2013-02-21 Laboratoy Skin Care, Inc. Fine dry particulate adenosine compositions and topical formulations including the same
US20100285611A1 (en) * 2009-05-06 2010-11-11 Ostafin Agnes E Photobleaching resistant ph sensitive dye nanoreactors with dual wavelength emission
GB0909183D0 (en) * 2009-05-28 2009-07-08 Bedi Kathryn J Coating method
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
US9095510B2 (en) 2009-11-10 2015-08-04 Laboratory Skin Care, Inc. Sunscreen compositions comprising uniform, rigid, spherical, nanoporous calcium phosphate particles and methods of making and using the same
US20110142889A1 (en) * 2009-12-16 2011-06-16 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
EP2512454A2 (en) 2009-12-16 2012-10-24 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
BR112013009635A2 (pt) 2010-10-19 2016-07-12 Elcelyx Therapeutics Inc terapias à base de ligante de receptor quimiossensorial
PH12013501524A1 (en) 2011-01-19 2022-10-26 Laboratory Skin Care Inc Topical minocycline compositions and methods of using the same
CO6540157A1 (es) * 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
CN103930115A (zh) * 2011-09-13 2014-07-16 阿尔塔克有限公司 药物纳米粒组合物
CN102580109B (zh) * 2012-03-02 2013-11-06 河南师范大学 一种抗癌药物载体及其制备方法
JP2015527310A (ja) 2012-06-28 2015-09-17 アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. 下気道および中枢気道への送達用微粒子製剤ならびに製造方法
WO2014064710A1 (en) 2012-10-22 2014-05-01 Department Of Biotechnology A process for the prepartion of non-viral vector for delivery of nucleic acids by mucosal route
ES2873600T3 (es) 2013-02-05 2021-11-03 1Globe Health Inst Llc Nanopartículas biodegradables y clínicamente compatibles como vehículos de suministro de fármacos.
MY175420A (en) 2013-03-15 2020-06-24 Laboratory Skin Care Inc Fine dry particulate resveratrol active agent compositions and topical formulations including the same
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
EP3148590A1 (en) * 2014-05-30 2017-04-05 AbbVie Deutschland GmbH & Co. KG Highly drug-loaded poly(alkyl 2-cyanoacrylate) nanocapsules
JP7164950B2 (ja) 2014-10-31 2022-11-02 ユニバーシティー オブ ユタ リサーチ ファウンデーション 胆汁酸粒子の組成物及び方法
CN108351687B (zh) * 2015-09-04 2022-01-07 耶鲁大学 靶向胰腺和结肠的聚合胆汁酸纳米组合物
US10029031B2 (en) * 2015-10-28 2018-07-24 Warsaw Orthopedic, Inc. Bone void filler having sustained therapeutic agent release
WO2017181143A1 (en) 2016-04-15 2017-10-19 Generon (Shanghai) Corporation, Ltd. Use of il-22 in treating necrotizing enterocolitis
CA3046977A1 (en) * 2016-12-16 2018-06-21 Delphi Scientific, Llc Layered particles and processes thereof
US11110064B2 (en) * 2018-12-16 2021-09-07 SRM Institute of Science and Technology Gel formulation for treating diabetic foot ulcer infections
EP4106794A4 (en) 2020-02-19 2024-03-20 Evive Biotechnology (Shanghai) Ltd METHOD FOR TREATING TRANSPLANT AND HOST DISEASE
CN111349158B (zh) * 2020-03-06 2022-11-08 西北农林科技大学 一种奶山羊性控精液制备方法
CN118370728B (zh) * 2024-06-24 2024-11-08 山东则正医药技术有限公司 一种glp-1ra载药纳米颗粒和制剂及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4016252A (en) 1972-04-06 1977-04-05 Institut Pasteur Calcium phosphate gel for adsorbing vaccines
FR2181426B1 (pt) 1972-04-06 1974-12-20 Pasteur Institut
FR2466991A1 (fr) 1979-10-08 1981-04-17 Pasteur Institut Perfectionnement a la preparation d'allergene
FR2505657A1 (fr) 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
CA1291036C (en) 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0737750T3 (da) 1989-03-21 2003-09-01 Vical Inc Ekspression af exogene polynucleotidsekvenser i vertebrater
US5460830A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Biochemically active agents for chemical catalysis and cell receptor activation
US5178882A (en) 1990-06-22 1993-01-12 The Regents Of The University Of California Viral decoy vaccine
US5460831A (en) 1990-06-22 1995-10-24 The Regents Of The University Of California Targeted transfection nanoparticles
US5219577A (en) 1990-06-22 1993-06-15 The Regents Of The University Of California Biologically active composition having a nanocrystalline core
US5334394A (en) 1990-06-22 1994-08-02 The Regents Of The University Of California Human immunodeficiency virus decoy
US5464634A (en) 1990-06-22 1995-11-07 The Regents Of The University Of California Red blood cell surrogate
US5306508A (en) 1990-06-22 1994-04-26 The Regents Of The University Of California Red blood cell surrogate
US5462751A (en) 1990-06-22 1995-10-31 The Regeants Of The University Of California Biological and pharmaceutical agents having a nanomeric biodegradable core
JPH05238950A (ja) * 1991-04-22 1993-09-17 Sanwa Kagaku Kenkyusho Co Ltd 易吸収性ｖｉｐ製剤
ATE295895T1 (de) 1992-03-11 2005-06-15 Powderject Vaccines Inc Genetischer impfstoff gegen den immunschwäche virus
US5620896A (en) 1992-03-23 1997-04-15 University Of Massachusetts Medical Center DNA vaccines against rotavirus infections
EP0646178A1 (en) 1992-06-04 1995-04-05 The Regents Of The University Of California expression cassette with regularoty regions functional in the mammmlian host
US5273965A (en) * 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
FR2698560B1 (fr) 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5364838A (en) 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
US5456986A (en) 1993-06-30 1995-10-10 Carnegie Mellon University Magnetic metal or metal carbide nanoparticles and a process for forming same
US5506203C1 (en) 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
IL113817A (en) 1994-06-30 2001-03-19 Merck & Co Inc Polynucleotide vaccne for papillomavirus
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
US5629021A (en) 1995-01-31 1997-05-13 Novavax, Inc. Micellar nanoparticles
US5747001A (en) 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
IE80468B1 (en) 1995-04-04 1998-07-29 Elan Corp Plc Controlled release biodegradable nanoparticles containing insulin
US8333996B2 (en) 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5785975A (en) 1995-06-26 1998-07-28 Research Triangle Pharmaceuticals Adjuvant compositions and vaccine formulations comprising same
US5827822A (en) 1996-03-25 1998-10-27 Sangstat Medical Corporation Cyclosporin a formulations as nanoparticles
US5648097A (en) 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US5695617A (en) 1995-11-22 1997-12-09 Dow Corning Corporation Silicon nanoparticles
WO1998035562A1 (en) 1997-02-14 1998-08-20 Merck & Co., Inc. Polynucleotide vaccine formulations
US5898028A (en) 1997-03-20 1999-04-27 Novo Nordisk A/S Method for producing powder formulation comprising an insulin
US5891420A (en) 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US6355270B1 (en) * 1999-01-11 2002-03-12 The Regents Of The University Of California Particles for oral delivery of peptides and proteins
ID25592A (id) * 1999-01-18 2000-10-19 Lg Chemical Ltd Mikropartikel lipofilik yang mengandung obat protein atau anti gen formulasi yang terdiri dari mikropartikel tersebut
US20020068090A1 (en) 1999-02-03 2002-06-06 Bell Steve J. D. Calcium phosphate particles as mucosal adjuvants
US20020054914A1 (en) 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20040258763A1 (en) 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US6355271B1 (en) 1999-02-03 2002-03-12 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6183803B1 (en) 1999-06-11 2001-02-06 Biosante Pharmaceuticals, Inc. Method for processing milk
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US20030185892A1 (en) 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods

Also Published As

Publication number Publication date
EP1720520A2 (en) 2006-11-15
WO2005084637A2 (en) 2005-09-15
RU2006132735A (ru) 2008-03-20
MXPA06009222A (es) 2007-03-08
DE602005021756D1 (de) 2010-07-22
AU2005219372A1 (en) 2005-09-15
JP2007522228A (ja) 2007-08-09
CA2555921A1 (en) 2005-09-15
CN1993113B (zh) 2010-12-08
US20050234114A1 (en) 2005-10-20
EP1720520B1 (en) 2010-06-09
WO2005084637A3 (en) 2006-11-02
KR20070002014A (ko) 2007-01-04
US7651694B2 (en) 2010-01-26
CN1993113A (zh) 2007-07-04
JP5103022B2 (ja) 2012-12-19
ATE470433T1 (de) 2010-06-15
ES2344303T3 (es) 2010-08-24

Similar Documents

Publication Publication Date Title
DE602005021756D1 (de) Partikel mit kern aus calciumphosphat-nanopartikeln, biomolekül und gallensäure, herstellungsverfahren und therapeutische verwendung
WO2009135190A3 (en) Therapeutic calcium phosphate particles and methods of making and using same
EP1585756A4 (en) ADMINISTRATION OF SIRNAS
DE60314500D1 (de) Diaminopyrimidine und deren verwendung als angiogenesehemmer
ATE495739T1 (de) Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP2081435A4 (en) HAMMER OF BRUTON TYROSINE KINASE
BRPI0607728A2 (pt) complexo de lipoproteìna carregado reconstituìdo, composição farmacêutica, e, uso de um complexo de lipoproteìna carregado
EA200801406A1 (ru) Антагонисты активина-actriia и их применение для стимулирования роста кости
ATE526987T1 (de) Dr5-antikörper und deren verwendung
EA201170040A1 (ru) Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и способы их получения и применения
BRPI0514293A (pt) sais de dicetopiperazina, sais de dicetomorfolina ou sais de dicetodioxano para administração de droga
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200602137A1 (ru) Гидрогелевые препараты интерферона
DE60326859D1 (de) Arzneimittelverabreichung
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
MXPA05009743A (es) Composiciones con actividad hematopoyetica e inmune.
NO20082848L (no) Farmasoytisk formulering for behandling av osteoartritt inneholdende klodronsyre og hyaluronsyre
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
UA92593C2 (ru) Лечение мастита энрофлоксацином
ATE481392T1 (de) Benzimidazolderivate zur behandlung entzündlicher erkrankungen
ATE425212T1 (de) Tocopherolzusammensetzungen und verwendung
CY1115607T1 (el) Θεραπευτικες φαρμακοτεχνικες μορφες τελεστη αυξησης κερατινοκυτταρων

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A(S) 4A,5A E 6A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2099 DE 29/03/2011.